Interesting couple of days for OBJ as it waits fro results in February:
1. Looks like The Speculator is now on the OBJ story. This might help to explain some of the latest volumes.
2. OBJ Ltd (ASX: OBJ) noted the overnight publication by the Journal of
Pharmaceutical Science of a paper into the enhanced transdermal delivery of
Naltrexone by the Companys technology.
The paper is published by Wiley Interscience and the American Pharmacists and I believe that it is a peer reviewed journal. Still no guarantees for February but slowly starts to build some credibility in the lead-up to results. Not surprised the SP rose to 3.2c on this.
Holding OBJ at .007c
Has anyone in here run the calcs or come across what the Feb announcment is worth to the company or beter still on a per share basis for first 12 months if it is a positive announcment.... I read somewhere its a $13.?? Billion dollar anticipated market share or industry..... but whats the rofit margin and whats the expected uptakes on this product...
Obviously by the size of OBJ is huge, but anyone found a calculation yet...